title: Polymorphisms in the novel serotonin receptor subunit gene HTR3C show different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy.
abstract: The aim of this study was to correlate chemotherapy-induced nausea and vomiting (CINV) with commonly occurring single nucleotide polymorphisms (SNP) in the 5-hydroxytryptamine receptor 3 genes (HTR3). Women with breast cancer without previous chemotherapy were eligible for this prospective study. All patients received epirubicin, with or without cyclophosphamide, and preventive medication with ondansetron and dexamethasone. The patients documented every vomiting event on an hourly basis. Real-time polymerase chain reaction (PCR) analysis was performed for the following nonsynonymous SNPs: p.Y129S (HTR3B), p.K163N (HTR3C) and p.A405G (HTR3C). The overall proportion of patients (total n = 110) who reported vomiting in the first 24 h after chemotherapy was 31.8%. The variant genotype of K163N (HTR3C) was associated with vomiting, which occurred in 50.0% (P = 0.009). Polymorphisms in the HTR3C gene could serve as a predictive factor for CINV in patients undergoing moderately emetogenic chemotherapy.
authors.affiliation: University Breast Center Franconia, Erlangen University Hospital, Universitaetsstrasse 21-23, Erlangen, Bavaria, Germany. peter.fasching@gyn.med.uni-erlangen.de
authors.forename: P A
authors.initials: PA
authors.lastname: Fasching
authors.forename: B
authors.initials: B
authors.lastname: Kollmannsberger
authors.forename: P L
authors.initials: PL
authors.lastname: Strissel
authors.forename: B
authors.initials: B
authors.lastname: Niesler
authors.forename: J
authors.initials: J
authors.lastname: Engel
authors.forename: H
authors.initials: H
authors.lastname: Kreis
authors.forename: M P
authors.initials: MP
authors.lastname: Lux
authors.forename: S
authors.initials: S
authors.lastname: Weihbrecht
authors.forename: B
authors.initials: B
authors.lastname: Lausen
authors.forename: M R
authors.initials: MR
authors.lastname: Bani
authors.forename: M W
authors.initials: MW
authors.lastname: Beckmann
authors.forename: R
authors.initials: R
authors.lastname: Strick
mesh_terms: D018943:Anthracyclines / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000009:adverse effects; D003907:Dexamethasone / Q000627:therapeutic use; D015251:Epirubicin / Q000009:adverse effects; D005260:Female; D005838:Genotype; D006801:Humans; D009325:Nausea / Q000139:chemically induced / Q000235:genetics / Q000517:prevention & control; D017294:Ondansetron / Q000627:therapeutic use; D020641:Polymorphism, Single Nucleotide; D044406:Receptors, Serotonin, 5-HT3 / Q000235:genetics*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012307:Risk Factors; D014839:Vomiting / Q000139:chemically induced / Q000235:genetics* / Q000517:prevention & control
chemical_list: D018943:Anthracyclines; D000970:Antineoplastic Agents; D044406:Receptors, Serotonin, 5-HT3; D015251:Epirubicin; D017294:Ondansetron; D003907:Dexamethasone; D003520:Cyclophosphamide